Ligand Pharmaceuticals
LGND
293 hedge funds and large institutions have $3.35B invested in Ligand Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 52 funds opening new positions, 114 increasing their positions, 81 reducing their positions, and 21 closing their positions.
148% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 21
43% more funds holding in top 10
Funds holding in top 10: 7 → 10 (+3)
41% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 81
10% more capital invested
Capital invested by funds: $3.04B → $3.35B (+$315M)
10% more funds holding
Funds holding: 266 → 293 (+27)
3.53% less ownership
Funds ownership: 191.07% → 187.54% (-3.5%)
42% less call options, than puts
Call options by funds: $11.2M | Put options by funds: $19.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$53.8M |
| 2 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$39.6M |
| 3 |
BlackRock
New York
|
+$33.2M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$20.2M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$88.4M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
-$79.5M |
| 3 |
DMK
David M. Knott
|
-$25.4M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$24.7M |
| 5 |
CCMLC
Cardinal Capital Management LLC (Connecticut)
Greenwich,
Connecticut
|
-$22.6M |
LGND Hedge Fund Activity: Q3 2017 in Review
293 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q3 2017, worth a combined $3.35B — up 10% from $3.04B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new LGND positions and 21 closed out — a net gain of 31 holders — while 114 added to existing stakes and 81 trimmed.
The largest buyer was Bank of America, adding an estimated $53.8M. The largest seller was Scopia Capital Management, exiting entirely with an estimated $88.4M sold.
- 293 institutional investors held Ligand Pharmaceuticals (LGND) as of Q3 2017, up from 266 in Q2 2017.
- Funds reported $3.35B of Ligand Pharmaceuticals stock for Q3 2017, up 10% quarter-over-quarter.
- 52 funds opened new Ligand Pharmaceuticals positions in Q3 2017 and 21 closed out, a net change of +31 holders.
- The largest Ligand Pharmaceuticals buyer in Q3 2017 was Bank of America, an estimated $53.8M added.
- The largest Ligand Pharmaceuticals seller in Q3 2017 was Scopia Capital Management, an estimated $88.4M sold.
Based on aggregated 13F filings for Q3 2017.